» Articles » PMID: 32379923

Is BCG Vaccination Causally Related to Reduced COVID-19 Mortality?

Overview
Journal EMBO Mol Med
Specialty Molecular Biology
Date 2020 May 8
PMID 32379923
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

The ongoing severe acute respiratory sickness coronavirus 2 (SARS-CoV-2) pandemic has resulted in more than 3,600,000 detected cases of COVID-19 illness and nearly 260,000 deaths worldwide as of May 6, 2020. Recently, BCG vaccination was shown to correlate with reduced COVID-19 case fatality rates (preprint: Miller et al, 2020; preprint: Sala & Miyakawa, 2020; https://www.jsatonotes.com/2020/03/if-i-were-north-americaneuropeanaustral.html). The most recent data from publicly available resources also indicate that both COVID-19 incidence and total deaths are strongly associated with the presence or absence of national mandatory BCG vaccination programs. As seen in Table 1, seven of eight countries with very low numbers of total deaths (< 40 per 1 million population) adopted a mandatory BCG vaccination program using one of a set of 6 separate BCG strains (Table 1). In contrast, COVID-19 mortality was markedly higher in countries where BCG vaccination is not widely administered or is given only to high-risk groups. COVID-19 mortality was also higher in countries where widespread BCG vaccination was discontinued more than 20 years ago and in countries that used the BCG Denmark strain regularly or temporarily. This raises the question of whether BCG vaccination and reduced COVID-19 mortality are causally related. An additional question is why different BCG strains may be variably associated with mortality.

Citing Articles

BCG vaccination policy, natural boosting and pediatric brain and CNS tumor incidences.

Singh S, Diwakar A, Singh R Front Immunol. 2023; 14:1174006.

PMID: 37383238 PMC: 10295148. DOI: 10.3389/fimmu.2023.1174006.


Prevalence and functional profile of SARS-CoV-2 T cells in asymptomatic Kenyan adults.

Samandari T, Ongalo J, McCarthy K, Biegon R, Madiega P, Mithika A J Clin Invest. 2023; 133(13).

PMID: 37219944 PMC: 10313370. DOI: 10.1172/JCI170011.


Impact of the COVID-19 pandemic on routine vaccine landscape: A global perspective.

Basu S, Ashok G, Debroy R, Ramaiah S, Livingstone P, Anbarasu A Hum Vaccin Immunother. 2023; 19(1):2199656.

PMID: 37078597 PMC: 10294763. DOI: 10.1080/21645515.2023.2199656.


Recent developments in the immunopathology of COVID-19.

Zhang H, Sun Y, Wang Y, Yazici D, Azkur D, Ogulur I Allergy. 2022; 78(2):369-388.

PMID: 36420736 PMC: 10108124. DOI: 10.1111/all.15593.


BCG and SARS-CoV-2-What Have We Learned?.

Kulesza J, Kulesza E, Kozinski P, Karpik W, Broncel M, Fol M Vaccines (Basel). 2022; 10(10).

PMID: 36298506 PMC: 9610589. DOI: 10.3390/vaccines10101641.


References
1.
Liu J, Tran V, Leung A, Alexander D, Zhu B . BCG vaccines: their mechanisms of attenuation and impact on safety and protective efficacy. Hum Vaccin. 2009; 5(2):70-8. DOI: 10.4161/hv.5.2.7210. View

2.
Chen J, Islam S, Ren H, Liu J . Differential productions of lipid virulence factors among BCG vaccine strains and implications on BCG safety. Vaccine. 2007; 25(48):8114-22. DOI: 10.1016/j.vaccine.2007.09.041. View

3.
Behr M, Small P . A historical and molecular phylogeny of BCG strains. Vaccine. 1999; 17(7-8):915-22. DOI: 10.1016/s0264-410x(98)00277-1. View

4.
Ladefoged A, Bunch-Christensen K, GULD J . Tuberculin sensitivity in guinea-pigs after vaccination with varying doses of BCG of 12 different strains. Bull World Health Organ. 1976; 53(4):435-43. PMC: 2366516. View

5.
Ritz N, Curtis N . Mapping the global use of different BCG vaccine strains. Tuberculosis (Edinb). 2009; 89(4):248-51. DOI: 10.1016/j.tube.2009.03.002. View